FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
EMA Adopts a Revised Opinion for Enfortumab Vedotin After Further Safety Information Emerged During the Decision-Making Process
It is intended for the treatment of adult patients with urothelial cancer
Risk Estimates of Small Bowel Cancer in Inflammatory Bowel Disease
Findings from a large, prospective cohort study of patients with inflammatory bowel disease diagnosed in Norway and Sweden
Survivors of Childhood, Adolescent, and Young Adult Cancer Not at Increased Risk of Testing Positive for COVID-19, nor for Serious Sequelae when Contracting Infection
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage NSCLC
Efficacy was evaluated in CHECKMATE-816 study
German National Network Genomic Medicine Suggests a Novel Classification of Atypical EGFR Mutations
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors
EMA Recommends Extension of Therapeutic Indications for Abemaciclib
New indication concerns the use in patients with early breast cancer at high risk of recurrence
Addition of a Live Bacterial Product Enhances the Clinical Outcome in Patients with mRCC Treated with Nivolumab-Ipilimumab Combination
Promising clinical benefit associated with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders
No Impact on Survival from Dose Reduction and Interruption for the Management of Olaparib Associated Adverse Events
SOLO2 ancillary study findings will help assure patients that their outcomes will not be adversely affected when dose reductions or interruptions are needed
EMA Recommends Extension of Therapeutic Indications for Nivolumab
New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma
Humoral Response to the Third Dose of the mRNA-based COVID-19 Vaccine in a Large Cohort of Patients with Cancer
Most patients were on active anticancer treatment during the 28 days before the administration of third dose
Lung Metastases, Cytoreductive Nephrectomy and Favourable Risk Group Associated with a Higher Probability of Response to First-Line Combination Therapy in mRCC
Findings from the international metastatic renal cell database consortium